30 results about "Polyomavirus JC" patented technology

Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.

The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

The present invention includes compositions and methods for the development and use of a vaccine that includes one or more JC virus antigens in a carrier adapted to trigger a JC virus-specific immune response in the human intestinal tract.

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.

The invention discloses a JC virus detection method. The JC virus detection method comprises the following steps: extracting JCV DNA from human urine sample by utilizing a paramagnetic particle method, thereby obtaining a sample to be detected; performing PCR amplification reaction; utilizing a fluorescent quantitative PCR meter to detect reaction results, and when collecting fluorescent signals, setting fluorescein corresponding to a fluorescent group at Taqman fluorescent probe JCV-FP 5' end to collect the fluorescent signals at 60 DEG. The invention further provides a kit for detecting the JC virus. The detection method is high in sensitivity, can detect to 500 copies/mL at the lowest extent; and meanwhile, the specificity of the detection method is good, and according to the detection method, and no cross reaction with other virus occurs, such as BK virus (BKV), hepatitis C virus (HCV), human cytomegalovirus (HCMV), and hepatitis B virus (HBV).

According to the present invention, a means of estimating the place of origin of a test subject by quickly and conveniently determining the genome type of JC virus infecting a test subject is provided. The present invention relates to a set of oligonucleotide probes for determining the genome type of JC virus infecting a test subject, such set containing: oligonucleotide probes (a-1) and (a-2); oligonucleotide probes (b-1) and (b-2); oligonucleotide probes (c-1) and (c-2); oligonucleotide probes (d-1), (d-2), (d-3), and (d-4); oligonucleotide probes (e-1), (e-2), and (e-3); oligonucleotide probes (f-1), (f-1), and (f-3); oligonucleotide probes (g-1), (g-2), and (g-3); oligonucleotide probes (h-1), (h-2), (h-3), and (h-4); oligonucleotide probes (i-1) and (i-2); oligonucleotide probes (j-1), (j-2), and (j-3); oligonucleotide probes (k-1), (k-2), and (k-3); and oligonucleotide probes (l-1) and (l-2).

The invention relates to the field of medical molecular biology detection, in particular to a primer and a probe capable of simultaneously detecting a BK virus and a JC virus, and a purpose. The invention provides a primer group capable of simultaneously detecting the BK virus and the JC virus. The primer group is designed on the basis of nucleotide sequences disclosed by SEQ ID NO.1 and SEQ ID NO.2, the above target sequence can meet a primer design requirement in a range of 100-200bp, meanwhile, the primer designed on the basis of the target sequence can effectively authenticate the BK virusand also can accurately authenticate the JC virus, and difficulty to design a fragment suitable for the primer is high.

The invention discloses a method for detecting JC polyoma virus through real-time fluorescent quantitative PCR (Polymerase Chain Reaction), provides a group of forward primers, reverse primers and probes for detecting JC virus in a biological product through real-time fluorescent quantitative PCR, and provides a PCR program for carrying out fluorescent quantitative PCR detection by utilizing the forward and reverse primers and the probes. The detection method provided by the invention can be used for detecting all JC viruses of different genotypes, is good in specificity, high in sensitivity and high in variant coverage, and compared with common virus cell culture detection, the detection time is greatly shortened, the labor and material cost is saved, and the detection method is suitable for complex detection of large-batch production of biological products.

The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, or at least one argonaute protein, which target at least one nucleotide sequence of the JCV genome.

The invention relates to a reagent for detecting a BK virus and a JC virus and application, and belongs to the technical field of biological medicines. A section of JCV fragment notch region exists in highly conserved regions of BKV and JCV. A primer probe system for simultaneously targeting BKV and JCV is designed at a suitable position beyond the notch region, and a reverse primer is only designed in the notch region to specifically target BKV or JCV. The reagent is used for preliminary screening, BKV and JCV are targeted at the same time, and resource saving is facilitated; and BKV or JCV can be accurately judged, and the reagent is suitable for clinical popularization. According to the invention, BKV and JCV activation can be prevented, the treatment effect of related diseases can be evaluated in time, the defects and deficiencies of the existing detection system are made up, and the detection result is more reliable. BKV and JCV are taken into consideration, primary screening can be carried out by targeting BKV and JCV at the same time, BKV or JCV can be accurately judged, and timely immunosuppression adjustment is facilitated.